Latest News
All Times Eastern
- Will the ECB hike rates or not? Decision set to be cliff hanger as eurozone sentiment indicators deteriorate
- DocuSign shares rise after earnings, and other movers
- Barron's DocuSign, Apple, Smartsheet, Guidewire Software, RH, and More Stock Market Movers
- U.S. stock futures lean higher after difficult week on Wall Street
- Barron's Banks Are Stuck in a Rut. A Buyout Wave Could Be Building.
- Barron's High-Quality Dividend Stocks Are on Sale. Now Is the Time to Buy.
- Barron's Why Walt Disney Could Cave First in Its Cable Standoff With Charter
- Barron's 5 Federal Deficit Myths, Explained
- Barron's Walgreens Is Looking for a New CEO. Why That Could Make the Stock a Winner.
- Barron's Active Funds Rocked August. Passive Is Grabbing the Year.
to be replaced
Illumina Inc.
ILMNUS
$
0.71
0.45%
After Hours
$
159.56
After Hours Volume:
72.53K
| Close | Chg | Chg % |
|---|---|---|
| $158.85 | -1.14 | -0.71% |
Volume: 1.72M
65 Day Avg: 1.53M
156.14
Day Range
159.79
156.14
52 Week Range
248.87
Partner Center
Your Watchlists
Recently Viewed Tickers
Overview
ILMN Overview
Key Data
- Open $158.91
- Day Range 156.14 - 159.79
- 52 Week Range 156.14 - 248.87
- Market Cap $25.33B
- Shares Outstanding 158.3M
- Public Float 157.62M
- Beta 1.12
- Rev. per Employee $387.91K
- P/E Ratio N/A
- EPS -$26.65
- Yield N/A
- Dividend N/A
- Ex-Dividend Date N/A
- Short Interest 5.79M 08/15/23
- % of Float Shorted 3.67%
- Average Volume 1.53M
Performance
| 5 Day |
|
| 1 Month |
|
| 3 Month |
|
| YTD |
|
| 1 Year |
|
Analyst Ratings
Number of Ratings 23
Full Ratings
Recent News
Biotech and Pharma Illumina Slashes Guidance Amid ‘Cautious’ Consumer. What Wall Street Thinks.
Biotech and Pharma Illumina to Appeal $476 Million EU Fine for Closing Grail Acquisition Early
Financials A Schwab Wealth Survey Reveals a Paradox
Biotech and Pharma Illumina CEO’s Resignation May Restore Stock’s Popularity
Why Is Illumina Stock Trading Lower Today?
on Benzinga.com
Is Illumina (ILMN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
Is Illumina (ILMN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
on GuruFocus.com
11 Analysts Have This to Say About Illumina
on Benzinga.com
Is Illumina (ILMN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
Is Illumina (ILMN) Too Good to Be True? A Comprehensive Analysis of a Potential Value Trap
on GuruFocus.com
RBC Capital Remains a Buy on Illumina (ILMN)
on TipRanks.com
SVP of Illumina Sold $83K In Stock
on Benzinga.com
Peering Into Illumina's Recent Short Interest
on Benzinga.com
Is Illumina Inc (ILMN) a Hidden Value Trap? A Comprehensive Analysis
Is Illumina Inc (ILMN) a Hidden Value Trap? A Comprehensive Analysis
on GuruFocus.com
Is Illumina Inc. (ILMN) a Hidden Value Trap? An In-Depth Analysis
Is Illumina Inc. (ILMN) a Hidden Value Trap? An In-Depth Analysis
on GuruFocus.com
Is Illumina Inc (ILMN) a Hidden Value Trap? A Comprehensive Analysis
Is Illumina Inc (ILMN) a Hidden Value Trap? A Comprehensive Analysis
on GuruFocus.com
Illumina Inc.
Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through the Core Illumina segment, which serves customers in the research, clinical and applied markets fields, and enables the adoption of a variety of genomic solutions. The firm's products include instruments, kits and reagents, selection tools, and software and analysis. Its services include sequencing and microarray services, proactive instrument monitoring, and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.
Competitors
| Name | Chg % | Market Cap |
|---|---|---|
| Laboratory Corp. of America Holdings | $18.13B | |
| Charles River Laboratories International Inc. | $10.48B | |
| Quest Diagnostics Inc. | $14.27B | |
| 10x Genomics Inc. | $6.13B | |
| Incyte Corp. | $14.16B | |
| Pacific Biosciences of California Inc. | $2.78B | |
| BGI Genomics Co. Ltd. | ¥21.89B | |
| Exelixis Inc. | $7.07B | |
| Invitae Corp. | $232.7M |